Daily Archives: May 15, 2018
StackPath ควบรวมกับ Server Density
นำเสนอการตรวจสอบชั้นนำของอุ
องดัลลัส, May 15, 2018 (GLOBE NEWSWIRE) — Server Density ผู้ให้บริการตรวจสอบโครงสร้างพื้
“เราตื่นเต้นที่จะได้ Server Density มาเป็นส่วนหนึ่งของบริษัทของเรา มันเป็นความสมกันที่สมบูรณ์แบบ” นาย Lance Crosby ผู้ก่อตั้ง ประธาน และซีอีโอของ StackPath กล่าว “StackPath มีความมุ่งมั่นสูงสุดในการให้
เอเย่นต์ตรวจสอบของ Server Density ถูกติดตั้งในเซิร์ฟเวอร์หลายล้
“เราสร้าง Server Density ขึ้นมาจากความขุ่นมัวว่า เครื่องมือตรวจสอบถ้าไม่มี
HumanOps เป็นทรัพยากรที่ดีเยี่ยมและมี
ในเดือนธันวาคม 2558 Server Density ระดมเงินทุนได้ 1.5 ล้านดอลลาร์ ในการ seed funding นำโดย SP Ventures ก่อนหน้านี้ พวกเขาก็ระดมเงินทุนได้ 50,000 ยูโร จาก Seedcamp และจากนักลงทุน angel ต่างๆ เช่น Christoph Janz, Dick Williams, Qamar Aziz และผู้อื่น ๆ รายละเอียดทางการเงินของธุ
เกี่ยวกับ StackPath
StackPath เป็นแพลตฟอร์มให้บริการรั
เกี่ยวกับ Server Density
Server Density ให้บริการตรวจสอบโครงสร้างพื้
สำหรับข้อมูลเพิ่มเติม สื่อและนักวิเคราะห์สามารถติดต่
Susie McDonald
StackPath
VP Corporate Communications
susan.mcdonald@stackpath.com
503-806-3841
At-Sunrice GlobalChef Academy, Singapore Announces Professor Hervé This as Keynote Speaker for Graduation and Global Alumni Reunion Week Celebrations
World Renowned Innovator and Father of Molecular Gastronomy, Dr. This will speak on the theme of “Cooking: Love, Art & Technique”
SINGAPORE, May 15, 2018 (GLOBE NEWSWIRE) — At-Sunrice GlobalChef Academy, the premier school for culinary, pastry, baking and food & beverage service courses in Singapore, announced today that Dr. Hervé This, the French chemist celebrated as the father of molecular gastronomy and the creator of “note by note cooking”, will be the keynote speaker at their 2018 graduation ceremony and alumni week celebrations the week of June 25th.
A physical chemist at France’s National Institute for Agricultural Research, Dr. This is regarded as a true culinary revolutionary who has spent his career bringing science into the kitchen, both to explain traditional cooking and then to dismantle it. Hailed by The New York Times as “France’s favorite gastronomic mad scientist,” Dr. This is one of the two founders of molecular gastronomy, a subdivision of food science that emphasizes the chemical components of cooking and food.
Dr. This has also pioneered a new technique called “Note-by-Note” cooking – building food from pure chemical compounds which can help eliminate food waste and eventually end world hunger. Note by Note cooking bypasses traditional ingredients like vegetables, meat and fruit in favor of their underlying compounds like protein, lipids, saccharides, phenolics, etc. – which it reassembles for an endless range of culinary possibilities. “If you use pure compounds, you open up billions and billions of new possibilities,” said This. “It’s like a painter using primary colours or a musician composing wave by wave with a synthesizer.”
“We are thrilled to have Dr. Hervé This join us for our 2018 graduation celebration and global alumni reunion week,” said Dr. Kwan Lui, founder of At-Sunrice GlobalChef Academy. “Dr. This’ theories and techniques have absolutely revolutionized cooking and inspired a new generation to rethink what cooking is and can be. His often controversial yet always thought-provoking scientific approach is never separated from his clear passion for cooking and the joy that it can bring. Our alumni, graduates and guests will learn more than they can possibly imagine from him.”
At-Sunrice Graduation Week is the largest event and celebration the academy holds every year and spans a week of lectures, galas, and showcases. Dr. This will hold events and lectures at venues including Science Centre Singapore, the National University of Singapore and the facilities of At-Sunrice GlobalChef Academy. On Friday, June 29th, Dr. This will supervise a Note by Note Gala Dinner for government partners, industry leaders, graduates and alumni of At-Sunrice, and representatives from the media.
About At-Sunrice GlobalChef Academy
At-Sunrice GlobalChef Academy has been cultivating global chefs and F&B professionals in an experiential environment of culinary authenticity, best-fit apprenticeship and innovation since 2001. With an internationally experienced faculty and staff, state of the art facilities and strong industry partnerships, the Academy delivers skills and knowledge in East and West, Old and New World Cuisines, Herbs and Spices, Innovation and Technology as well as enables the diploma students to spend their last six months in a paid Overseas Industrial Attachment.. At-Sunrice GlobalChef Academy is the first culinary academy in Singapore to be awarded the National Continuing Education and Training Institution (NCI) accreditation, allowing the academy to administer nationally-recognized diplomas that offer up to 70 percent fee subsidies for Singaporeans and permanent residents. It was also the first culinary school to be awarded the EduTrust 4-year certification from the Committee for Private Education (CPE). At-Sunrice students are from 32 countries, with many already degree and diploma holders in other disciplines who choose At-Sunrice to pursue their passion in food, food service and entrepreneurship For more information about At-Sunrice visit www.at-sunrice.com.
Amanda Liok At-Sunrice Global Chef Academy 6564166688 amanda_liok@at-sunrice.edu.sg
NetSpeed Furthers Leadership in Industrial, Factory Automation and Safety-critical Flight Systems with IEC 61508 Certification
SAN JOSE, Calif., May 15, 2018 (GLOBE NEWSWIRE) — NetSpeed Systems, Inc. today announced that its interconnect IP portfolio is now certified for the IEC 61508 functional safety standard. SGS-TÜV Saar GmbH, an independent accredited assessor, certified the IP in accordance with IEC 61508 Safety Integrity Level 3 (SIL3), the highest level possible for an IP-only component. NetSpeed’s pre-certified functional safety interconnect IP helps customers save time in developing and certifying their safety-critical applications.
Functional safety (FuSa) is increasingly important in industrial, factory automation and safety-critical flight systems with a focus on fail-operational SoC modes. IEC 61508 certification is regarded as the gold standard for electrical/electronic/
“The IEC 61508 standard is the cornerstone for developing safe solutions for industrial and other safety-critical markets,” said Wolfgang Ruf, head of Functional Safety Semiconductor at SGS-TÜV Saar GmbH. “NetSpeed IP has undergone a rigorous process and has successfully demonstrated that its products meet the stringent requirements for certification.”
An off-shoot of IEC 61508, the ISO 26262 automotive functional safety standard has been widely adopted for the automotive segment. NetSpeed previously announced ISO 26262, ASIL D-Ready certification for its cache coherent interconnect solution. The company is one of the first IP suppliers to achieve compliance with both ISO 26262 and IEC 61508.
“At NetSpeed, we are committed to providing our customers with the most advanced solutions for safety-critical applications,” said Sundari Mitra, CEO of NetSpeed. “This certification validates our process, technology and commitment.”
About NetSpeed Systems
NetSpeed is at the heart of next-gen system-on-chip (SoC) applications that are transforming the way we interact with each other and how we connect with the world. Whether you are a hardware architect looking for cache coherency solutions to realize your ideas into silicon or a SoC designer looking for a high performance and efficient interconnect or a safety manager looking for solutions to build resilient, fault-tolerant systems—NetSpeed has a solution for you. Learn about how NetSpeed is bringing the power of artificial intelligence to SoC design and architecture at www.netspeedsystems.com.
Press Contact:
NetSpeed Newsroom
Pauline Shulman
415-375-0303
pauline@pshulman.com
Aviation and Aerospace Consulting Veterans Celebrate Successful Launch of Alton Aviation Consultancy
NEW YORK, May 15, 2018 (GLOBE NEWSWIRE) — Alton Aviation Consultancy is celebrating its successful first year as an independent boutique advisory firm focused on the aviation and aerospace industries.
Experienced consulting executives Adam Cowburn and John Mowry set out to serve the aviation community with an agile, client-centric approach that aligns with rapidly changing global market dynamics. They have been joined by seasoned aviation consultants Laetitia Achille and Jonathan Berger, both Managing Directors, in addition to Directors Ma Min and Adam Guthorn, and a global team of managers and associates.
“Alton is dedicated to delivering the objective, data-driven guidance and insight that our clients require to inform business decisions regarding capital allocation, resource prioritization, and risk management,” said Mowry, who previously was a leader of the aviation consulting practice at SH&E and ICF, and began his career with General Electric.
Alton advises aviation and aerospace companies across the entire value chain on strategy and business plan development, financial transaction support, and operational performance improvement. Clients include: airlines; lessors and aircraft financiers; aerospace manufacturers; maintenance, repair and overhaul (MRO) and aftermarket service providers; and the financial and investment community.
As a privately-held independent firm, Alton has no joint ventures, affiliations, or other business associations that divert principals from their singular mission – serving the best interests of their clients.
“Our independence, global market coverage, and experience across the entire aviation and aerospace value chain provide Alton with unique insight into the challenges faced by our clients, in addition to their end customers,” said Cowburn, former head of Asia-Pacific for aviation consulting firms SH&E and ICF.
“We are dedicated to making Alton synonymous with deep aviation domain expertise and a relentless focus on delivering tangible results for our clients,” said Berger. Prior to joining Alton, Mr. Berger was a vice president at SH&E and ICF, where he launched and led their global MRO advisory practice. Before that, he was the general manager of Delta Air Lines’ maintenance & engineering business responsible for the Europe, Africa and Middle East region.
Since its inception, Alton has performed numerous engagements supporting its aviation clients on a wide range of strategic, commercial, and operational matters. Engagements have ranged from commercial due diligence of aircraft lessors and their portfolios to strategic planning for independent MRO providers, due diligence support for private equity investors in aviation assets and operating businesses, and product studies for aerospace manufacturers seeking to bring new offerings to the market.
Headquartered in New York, Alton operates globally with offices in Hong Kong, Beijing, and Tokyo, providing clients a global perspective with local expertise.
To download Alton’s logo and photos of principals, click here: http://bit.ly/2KSliMz
Contact for Alton Aviation Consultancy:
Andy McGowan of Watkins McGowan
c: +1.404.834.3481
andy@watkinsmcgowan.com
A photo accompanying this announcement is available at http://resource.globenewswire.
Neuralstem Provides Business Update and Reports First Quarter 2018 Fiscal Results
GERMANTOWN, Md., May 15, 2018 (GLOBE NEWSWIRE) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, provides a business update and reported its financial results for the first quarter ended March 31, 2018 .
“We remain committed to the development of NSI-566, our lead stem cell therapy candidate, and were pleased to complete the first surgery in the second cohort of our ongoing Phase 1 clinical trial in patients with chronic spinal cord injury,” said Rich Daly, President & Chief Executive Officer. “We anticipate initiating a clinical trial for NSI-566 in chronic stroke in China and have targeted mid-2018 to begin dosing. We continue to pursue the development of NSI-189, our lead small molecule candidate for major depressive disorder (MDD) and look forward to meeting with the U.S. Food and Drug Administration in the second half of 2018 to formulate its clinical development path. We believe that NSI-189 may offer cognitive benefits in addition to antidepressant effects, which would distinguish it from other approved treatments for MDD.”
Clinical Highlights for Lead Clinical Programs
NSI-566, is a spinal cord-derived neural stem cell line that is being evaluated to treat paralysis associated with stroke, Amyotrophic Lateral Sclerosis (ALS) and chronic spinal cord injury (cSCI). NSI-566 is Neuralstem’s lead stem cell therapy candidate.
- Neuralstem announced the results from a study published in the Annals of Clinical and Translational Neurology in a manuscript entitled “Long-term Phase 1/2 Intraspinal Stem Cell Transplantation Outcomes in Amyotrophic Lateral Sclerosis” that support the potential of transplanted human spinal cord-derived neural stem cells (HSSC) to stabilize functioning of ALS patients. The study evaluated the impact of HSSC transplantation on functional outcomes, as measured using the ALSFRS-R scale, and on a composite statistic that combined functional and survival outcomes. Results were evaluated against matched controls derived from two historical datasets and showed significantly better ALSFRS-R scores at 24 months, as well as the composite functional/survival score in subjects receiving HSSC. The ALS Functional Rating Scale-Revised (ALSFRS-R) is a validated questionnaire that measures physical function in performing activities of daily living (ADLs). The manuscript was published on May 3, 2018.
- On March 28, Neuralstem completed the first surgery using NSI-566 spinal cord-derived neural stem cells in the second, cervical injury cohort of a Phase 1 clinical trial in patients with chronic spinal cord injury (cSCI). The patients in this cohort include complete injury patients with no motor or sensory function below injury. The clinical trial is being conducted at the University of California San Diego, Division of Neurosurgery. The clinical trial was expanded to include a new cohort of four qualifying patients with AIS-A complete, quadriplegic, cervical injuries involving C5-C7 of their spinal cord, after promising results were observed with the first cohort. The clinical trial is evaluating the safety and feasibility of using NSI-566 spinal cord-derived neural stem cells to repair cSCI.
NSI-189, a benzylpiperazine-
- In the second half of 2018, Neuralstem intends to meet with the U.S. Food and Drug Administration to discuss the clinical development path for NSI-189 in major depressive disorder.
Financial Results for the Quarter Ended March 31, 2018
Cash Position and Liquidity: Cash and investments was $9.7 million at March 31, 2018 as compared to $11.7 million at December 31, 2017. The $2.0 million decrease reflects a $2.1 million loss for the period adjusted for certain non-cash items including $240,000 of share-based compensation, $190,000 gain related to the change in fair value of our liability classified warrants and $180,000 net cash inflows related to changes in our operating assets and liabilities.
Operating Loss: Operating loss for the quarter ended March 31, 2018 was $2.3 million compared to a loss of $4.2 million for the comparable period of 2017. The decrease in operating loss for the year was primarily related to decreases in clinical trial and related costs due to the completion of the Company’s NSI-189 Phase 2 clinical trial coupled with decreases in personnel, facility and related expenses due to our ongoing corporate restructuring and cost reduction efforts.
Net Loss: Net loss for the quarter ended March 31, 2018 was $2.1 million, or $0.14 per share, compared to a loss of $7.6 million, or $0.68 per share, for the comparable period of 2017. The decrease in net loss was primarily due to a decrease in operating expenses and the non-cash charges related to the change in the fair value of the liability classified warrants and warrant inducement expenses in the 2017 period along with a decrease in interest expense related to our long-term debt which matured in April 2017.
Research and Development Expenses: The $1.2 million of research and development expenses for the quarter ended March 31, 2018 represents a $1.7 million, or 60% decrease over the comparable period of 2017. This decrease was primarily attributable to a $1.1 million decrease in clinical trial and related costs due to the completion of our NSI-189 Phase 2 clinical trial, a $200 thousand decrease in our personnel and facility expenses due to our ongoing corporate restructuring and cost reduction efforts and a $310 thousand decrease in our non-cash share-based compensation expense.
General and Administrative Expenses: The $1.2 million of general and administrative expenses for the quarter ended March 31, 2018 represents a $150 thousand, or 11% decrease over the comparable period of 2017. This decrease was primarily attributable to a $140 thousand decrease in payroll and related expenses coupled with a $50 thousand decrease in consulting and professional service expenses due to our corporate restructuring and cost reduction efforts partially offset by a $20 thousand increase in non-cash share-based compensation expense.
Liquidity: The Company expects its existing cash, cash equivalents and short-term investments to fund its operations based on our current operating plans, into the first quarter of 2019.
| Neuralstem, Inc. | |||||||
| Unaudited Condensed Consolidated Balance Sheets | |||||||
| March 31, | December 31, | ||||||
| 2018 | 2017 | ||||||
| ASSETS | |||||||
| CURRENT ASSETS | |||||||
| Cash and cash equivalents | $ | 9,724,248 | $ | 6,674,940 | |||
| Short-term investments | – | 5,000,000 | |||||
| Trade and other receivables | 137,372 | 312,802 | |||||
| Current portion of related party receivable, net of discount | – | 58,784 | |||||
| Prepaid expenses | 346,995 | 402,273 | |||||
| Total current assets | 10,208,615 | 12,448,799 | |||||
| Property and equipment, net | 149,668 | 172,886 | |||||
| Patents, net | 839,314 | 883,462 | |||||
| Related party receivable, net of discount and current portion | 334,303 | 365,456 | |||||
| Other assets | 18,048 | 13,853 | |||||
| Total assets | $ | 11,549,948 | $ | 13,884,456 | |||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
| CURRENT LIABILITIES | |||||||
| Accounts payable and accrued expenses | $ | 1,169,736 | $ | 875,065 | |||
| Accrued bonuses | – | 418,625 | |||||
| Other current liabilities | 109,266 | 220,879 | |||||
| Total current liabilities | 1,279,002 | 1,514,569 | |||||
| Warrant liabilities | 3,662,663 | 3,852,882 | |||||
| Other long term liabilities | 1,172 | 1,876 | |||||
| Total liabilities | 4,942,837 | 5,369,327 | |||||
| STOCKHOLDERS’ EQUITY | |||||||
| Preferred stock, 7,000,000 shares authorized, $0.01 par value; 1,000,000 shares issued and outstanding at both March 31, 2018 and December 31, 2017 | 10,000 | 10,000 | |||||
| Common stock, $0.01 par value; 300 million shares authorized, 15,160,014 shares issued and outstanding at both March 31, 2018 and December 31, 2017 | 151,600 | 151,600 | |||||
| Additional paid-in capital | 217,289,009 | 217,050,174 | |||||
| Accumulated other comprehensive income | 2,746 | 2,631 | |||||
| Accumulated deficit | (210,846,244 | ) | (208,699,276 | ) | |||
| Total stockholders’ equity | 6,607,111 | 8,515,129 | |||||
| Total liabilities and stockholders’ equity | $ | 11,549,948 | $ | 13,884,456 | |||
| Neuralstem, Inc. Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss |
Three Months Ended March 31, 2018 2017 Revenues$ 2,500 $ 2,500 Operating expenses: Research and development expenses 1,169,441 2,902,086 General and administrative expenses 1,182,054 1,332,421 Total operating expenses 2,351,495 4,234,507 Operating loss (2,348,995) (4,232,007) Other income (expense): Interest income 17,749 20,883 Interest expense (1,920) (138,732)Change in fair value of derivative instruments 190,219 (2,741,314)Warrant inducement and other expenses (4,021) (476,084)Total other income (expense) 202,027 (3,335,247) Net loss$ (2,146,968) $ (7,567,254) Net loss per share – basic and diluted$ (0.14) $ (0.68) Weighted average common shares outstanding – basic and diluted 15,116,937 11,140,898 Comprehensive loss: Net loss$ (2,146,968) $ (7,567,254)Foreign currency translation adjustment 115 (171)Comprehensive loss$ (2,146,853) $ (7,567,425)
Cautionary Statement Regarding Forward Looking Information:
This news release contains “forward-looking statements” made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and may often be identified by words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Specific risks and uncertainties that could cause our actual results to differ materially from those expressed in our forward-looking statements include risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem’s periodic reports, including its Annual Report on Form 10-K for the year ended December 31, 2017, and its Quarterly Report on Form 10-Q for the three months ended March 31, 2018, filed with the Securities and Exchange Commission (SEC), and in other reports filed with the SEC. We do not assume any obligation to update any forward-looking statements.
Contact:
Kimberly Minarovich
Argot Partners (Investor Relations)
212-600-1902
neuralstem@argotpartners.com
Invivoscribe Releases the LymphoTrack Dx TRB Assay as CE-Marked IVD Kit, Completing the NGS Clonality Suite for the MiSeq Platform
SAN DIEGO, May 15, 2018 (GLOBE NEWSWIRE) — Invivoscribe Technologies Inc., a global company with decades of experience providing clonality and biomarker test solutions for the fields of oncology and personalized molecular medicine, today announced the release of the LymphoTrack® Dx TRB Assay for the Illumina® MiSeq® platform, a CE-marked next-generation sequencing (NGS) assay kit for in vitro diagnostic (IVD) use. Invivoscribe is the only company offering a complete suite of CE-marked NGS clonality assays designed to assess clonality for both diagnostic and tracking purposes. The LymphoTrack Dx TRB Assay for the ThermoFisher Scientific® Ion PGM™ and Ion S5™ instruments will be released later this year.
Leukemias and lymphomas generally originate from the malignant transformation of individual lymphoid cells, causing the vast majority of lymphoid malignancies to share one or more cell-specific or “clonal” rearrangements. The LymphoTrack Dx TRB assay identifies clonal TRB Vβ-(Dβ-)Jβ rearrangement sequences, and the accompanying LymphoTrack Dx bioinformatics software provides a clear summary of the frequency distribution. These clonal sequences can be used to monitor minimal residual disease (MRD) in longitudinal studies, which track the disease as well as the effectiveness of therapies aimed towards their eradication.
The LymphoTrack Dx TRB Assay completes the menu of Invivoscribe’s CE-marked clonality assays on the MiSeq®, leveraging the unparalleled accuracy and sensitivity of next generation sequencing (NGS), enabling small and large laboratories alike to identify and track clonal rearrangements. Invivoscribe’s CE-marked clonality kits, which allow single step PCR library generation and come with bioinformatics software designed to run on standard Windows platforms within customer laboratories, allow for comprehensive multiplex testing of any combination of samples and LymphoTrack Dx assays (e.g. IGH Leader, IGH FR1, IGH FR2, IGH FR3, IGK, TRG, and TRB), thus significantly reducing both laboratory costs and turnaround times. Deep-sequencing NGS assays represent a significant improvement over existing PCR-based assays. They accurately identify the majority of gene rearrangement sequences, or clonotypes, which can subsequently be used for MRD tracking. Each kit includes user-friendly LymphoTrack Dx MiSeq® software that automates the sorting and tracking of each sample and target, interprets sequence data, and generates detailed reports.
“We are pleased to offer the first commercially available NGS CE-marked IVD TRB kit, with bioinformatics software, for clonality assessment and tracking. Innovative products like our NGS-based LymphoTrack Dx Assays directly benefit patients by guiding precision treatments and enabling exceptionally sensitive monitoring for disease reoccurrence,” said Dr. Jeffrey Miller, CSO and CEO of Invivoscribe.
About Invivoscribe
Invivoscribe Technologies, Inc. is a privately held biotechnology company dedicated to improving the quality of healthcare worldwide by providing high quality, standardized reagents, tests, and bioinformatics tools to advance the fields of personalized molecular diagnostics and personalized molecular medicine. The extensive product portfolio includes RUO test kits, CE-marked IVDs, including IdentiClone®, LeukoStrat® and LymphoTrack Dx Assays with LymphoTrack Dx Software to assess clonality, somatic hypermutation and monitor MRD. Invivoscribe’s PCR and NGS-based tests, reagents and bioinformatics tools are currently being used in more than 700 clinical and research laboratories in more than 160 countries. Invivoscribe currently has clinical laboratories located in the U.S.A., Europe and Japan which provide international access to harmonized CLIA, CAP, and ISO 15189 accredited clinical testing and contract research organization (CRO) services. Invivoscribe’s clinical laboratories also offer comprehensive MyAML®, MyHeme®, MyMRD®, and custom gene panels, that when used in combination with Invivoscribe’s proprietary MyInformatics™ Software can identify and track primary driver mutations as well as the subclonal architecture and emergence of new driver mutations in patients with hematologic disease. Invivoscribe also has a subsidiary in Shanghai, China that is now supporting clinical trial work in China. Invivoscribe has a successful track record of partnerships with global pharmaceutical companies developing and commercializing companion diagnostics. As a world leader, Invivoscribe has long embraced the value of quality systems, and develops all innovative products, including bioinformatics software in compliance with ISO 13485 design controls, making them eligible to be submitted to worldwide regulatory authorities for registration.
For additional information please visit www.invivoscribe.com.
CONTACT:
Kevin Dobyns 858-224-6600
NTT Security Announces Expansion of Advanced Security Services in India and Philippines
SINGAPORE, May 15, 2018 (GLOBE NEWSWIRE) — NTT Security, the specialized security company of NTT Group, has announced expansion into India and Philippines as part of its strategic growth plan. It will provide Managed Security Services (MSS) and Security Consulting Services based on its strength in Global Threat Intelligence and Cyber Threat Advanced Analytics accumulated through global operations. This will enable more effective and sophisticated cybersecurity solutions for enterprises and governments as well as global companies which have business operations in the regions.
The latest move forms part of plans from the specialized security company of NTT Group to become a leading MSS provider in the Asia-Pacific region – just four months after it launched the same service for digital enterprises and governments in Thailand.
Both India and the Philippines recognise the positive impact that technology brings. The Indian government, for example, is pressing ahead with its Digital India programme to transform India into a digital economy. An IDC study commissioned by Microsoft reveals that digital transformation will add an estimated USD $154 billion to India’s GDP by 2021. A similar study predicts that around 40% of the Philippines’ GDP will be derived from digital products or services. It also shows 93% of organizations in the Philippines are already in the midst of their digital transformation journey.
“A push towards a digital economy is changing the way businesses and governments are run but there can be no digital economy without security,” says Martin Schlatter, CIO and Regional CEO for NTT Security in APAC. “Just as in any other nation, cyber criminals will take advantage of organizations in India and the Philippines that fail to adequately secure their digital assets. Cyber threats will evolve as technology evolves, which is why we are seeing an increased need for MSS providers to reduce the pressure and provide better security threat management.”
According to Frost & Sullivan, the MSS market in India alone has grown by 24.1% year-on-year, owing to the rising demand in cybersecurity solutions driven by the government’s drive for digitization through its Digital India campaign. Furthermore, sectors such as banking and finance, manufacturing, aviation, healthcare, and retail are increasingly adopting digital practices – many of which also face strict security compliance guidelines as a result. Many will therefore be relying on outsourcing security services to a trusted and reputable third party provider.
To support such challenges, NTT Security is also expanding a Security Operations Center (SOC) in Bangalore, India. The facility will comprise local teams and analysts across multiple disciplines, also leveraging NTT Security’s global capabilities, to protect organizations’ IT environments from security attacks. The SOC is expected to grow rapidly, so NTT Security will be looking to recruit people in India with a passion for, and experience in, cybersecurity and risk management.
Martin adds: “Along with our highly skilled security experts, our proprietary MSS platform can help protect organizations across a range of sectors against multiple and complex security threats around the clock. It can also provide optimized security through our unique insight, advanced analytics and applied threat intelligence over and above what can usually be done in-house.”
The MSS solution will be taken to market through the NTT Group companies of Dimension Data, NTT Communications and NTT DATA. As a centre of excellence, NTT Security is committed to continued investment in the creation of innovative security services, and continues to expand its reach together with NTT Group companies, while improving its strength in global threat intelligence and advanced analytics by collaboration with NTT R&D and alliances with technology partners.
Notes for editors:
About NTT Security
NTT Security is the specialized security company and the center of excellence in security for NTT Group. With embedded security we enable NTT Group companies to deliver resilient business solutions for clients’ digital transformation needs. NTT Security has 10 SOCs, seven R&D centers, over 1,500 security experts and handles hundreds of thousands of security incidents annually across six continents.
NTT Security ensures that resources are used effectively by delivering the right mix of Managed Security Services, Security Consulting Services and Security Technology for NTT Group companies – making best use of local resources and leveraging our global capabilities. NTT Security is part of the NTT Group (Nippon Telegraph and Telephone Corporation), one of the largest ICT companies in the world. Visit nttsecurity.com to learn more about NTT Security or visit http://www.ntt.co.jp/index_e.
For more information, please contact:
Origin Communications
t. +44 (0)20 3814 2940
e. nttsecurity@origincomms.com
NTT Security
Yixuan Lin
e. yixuan.lin@nttsecurity.com
